Dougal Thring has over 12 years of experience in leading all aspects of clinical development of Phase I and Phase II clinical studies for numerous domestic and international biotechnology companies.
Prior to becoming vice president of clinical development at Neuroscientific Biopharmaceuticals in March 2021, Mr Thring was the head of clinical solutions at Linear Clinical Research, an early-phase Australian contract
research organisation, where he was responsible for identifying the best clinical strategy for the initiation and completion of early-stage clinical programs for their clients.
Mr Thring holds a Bachelor of Medical and Pharmaceutical Biotechnology (1st Class Honours) from the University of South Australia, and a Masters of Pharmaceutical Medicine from the University of New South Wales.
